A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Sponsor AstraZeneca

Active, not recruiting

Phase

III

Age

≥18

Enrollment Goal

594

Interventions

ceralasertib (AZD6738), 
durvalumab (Imfinzi), 
docetaxel 

Modalities

Chemotherapy, Immunotherapy, Monoclonal Antibody, Signal Transduction Inhibitor
First Posted
Jul 11, 2022
Start
Sep 15, 2022
Last Updated
Oct 2, 2024

This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

Call
or
to speak with a clinical trial navigator about trials that match your diagnosis and treatment history.

Eligibility Criteria

Inclusion Criteria:

  • Histologically or cytologically documented NSCLC that is locally advanced or metastatic according to Version 8 of the IASLC Staging Manual in Thoracic Oncology.
  • Documented epidermal growth receptor factor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type status as determined at a local laboratory.
  • Documented radiological PD whilst on or after receiving the most recent treatment regimen.
  • Eligible for second- or third-line therapy and must have received an anti-PD-(L)1 therapy and a platinum doublet containing therapy for locally advanced or metastatic NSCLC either separately or in combination.
  • Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status of 0 or 1.
  • Adequate organ function and marrow reserve
  • Minimum life expectancy of 12 weeks.
  • Body weight > 30 kg and no cancer-associated cachexia.
  • Negative pregnancy test (serum test) for women of childbearing potential (WOCBP).

Exclusion Criteria:

  • Participant with mixed SCLC and NSCLC histology.
  • History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention.
  • Persistent toxicities (CTCAE Grade > 2) caused by previous anticancer therapy.
  • Active or prior documented autoimmune or inflammatory disorders.
  • Participants who have received more than one line of prior anti-PD-(L)1, either alone or in any combination.
  • Participants:

    1. Must not have experienced a toxicity that led to permanent discontinuation of the prior anti-PD(L)1 therapy.
    2. All AEs while receiving prior anti-PD(L)1 therapy must have completely resolved.
    3. Must not have experienced a Grade ≥ 3 immune-mediated adverse event (imAE) or an immune-related neurologic or ocular AE of any grade while receiving prior anti-PD(L)1 therapy.
    4. Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of > 10 mg prednisone or equivalent per day.
  • Participants who have received more than one prior line of platinum-based chemotherapy in metastatic setting.
  • Participants who have received a prior ataxia telangiectasia and Rad3-related protein (ATR) inhibitor.

Arms and interventions

Arm
Intervention/treatment
Experimental:
Participants will be administered ceralasertib orally followed by durvalumab administered intravenously.
Group A: Ceralasertib plus durvalumab combination therapy
Drug : Ceralasertib
Participants will receive ceralasertib oral tablets.
Drug : Durvalumab
Participants will receive durvalumab as an intravenous infusion.
Active Comparator:
Participants will be administered docetaxel (standard of care) administered intravenously.
Group B: Docetaxel monotherapy
Drug : Docetaxel
Participants will received docetaxel as an intravenous infusion.

Allocation

Randomized

Outcome Measures

Primary outcome measures

  • Overall Survival (OS) (Every 3 months (± 1 week) following objective progression of disease (PD) or treatment discontinuation (up to three years))

Secondary outcome measures

  • Progression-Free Survival (PFS) (Up to 3 years)
  • Objective Response Rate (ORR) (Up to 3 years)

More Information

Official title

LATIFY: A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY

Estimated trial completion date

Aug 22, 2025